Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. - Wikidata - awgldk - TriplyDB

Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q36402141

about

Non-alcoholic fatty liver disease: what the clinician needs to know.Role of Hedgehog Signaling Pathway in NASH Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?HCV derived from sera of HCV-infected patients induces pro-fibrotic effects in human primary fibroblasts by activating GLI2 Molecular Pathogenesis of NASH Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.Recent advances in hepatocellular carcinoma therapy.Developmental origins of NAFLD: a womb with a clue.Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.Autocrine Sonic hedgehog attenuates inflammation in cerulein-induced acute pancreatitis in mice via upregulation of IL-10.Alcohol activates the hedgehog pathway and induces related procarcinogenic processes in the alcohol-preferring rat model of hepatocarcinogenesis.NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.Steatosis and steatohepatitis: complex disorders.Sonic hedgehog signaling in the lung. From development to disease.Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism.Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E: therapeutic implications for nonalcoholic steatohepatitis Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis.PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis Interleukin-1β attenuates myofibroblast formation and extracellular matrix production in dermal and lung fibroblasts exposed to transforming growth factor-β1 The biliary epithelium gives rise to liver progenitor cells The Protective Effect of Resveratrol on Concanavalin-A-Induced Acute Hepatic Injury in Mice Reemergence of hedgehog mediates epithelial-mesenchymal crosstalk in pulmonary fibrosis.Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease.A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver.Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease Hedgehog pathway and pediatric nonalcoholic fatty liver disease.Role of hepatic progenitor cells in nonalcoholic fatty liver disease development: cellular cross-talks and molecular networks.Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.Hedgehog signaling pathway as key player in liver fibrosis: new insights and perspectives.Management and diagnosis of fatty liver disease.Antifibrotic therapies in the liver.Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis.Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

P2860

Q24563068-356D69FE-0D8A-46FE-B80E-26D30EAB8C03 Q26743373-48A93AB4-D5C5-43AF-8495-29D4050EB8E5 Q26992106-F085DC76-5676-4E35-944D-54DA323A6DD5 Q26998093-E90C6589-3815-497E-8D3C-CF7C810C3EEE Q27468911-33E8DB8A-9FAB-4110-8076-4762B71B6697 Q28071265-597CA16F-88E2-491C-9AFF-1BC4C35245BC Q28071596-B050029C-FE5C-4693-8C85-7668A21D231D Q28082065-A193CAAD-B509-4202-9D2A-45862776931A Q30236010-AC459B9E-2D35-42BF-B72B-E7269781794F Q30241940-B33B3C10-7AA5-4D1A-99D6-6E465D7A8CE1 Q30365017-2096927B-CA8E-4B19-B83D-3F91C29E120C Q30375036-CE55A63A-937B-498C-8AEA-B1717B802B31 Q30375693-E80384BB-2727-4C32-AB49-6829F556C733 Q31089713-136658CC-8337-4697-9497-E800CDC8AEAA Q33745654-B7827687-3A70-4BD8-A45E-834F1E8C9154 Q33844463-188631F0-B27C-4A51-B203-5474998C7A0E Q33907632-496D687E-9EE0-42CB-AE3D-D03288FE60E9 Q34431127-93B512E5-FDFC-4CFA-9D76-17F266020650 Q34560114-0AFFDDEB-B786-4E96-AF4C-B6342E6CB1D4 Q34636500-7395A7C4-6155-413A-AD24-FD6FCD80AB76 Q34777399-49E41A51-BD09-4DF9-A93C-9094E064ED69 Q34876724-5276928B-5B87-4309-8E36-A17A10A9646F Q34985968-E5503ABB-5D9D-4549-86EB-165B9A99EF2C Q35118918-031BF738-C52A-4969-BA63-DEE6BC2E01CB Q35539601-33CE827F-8978-491D-A23C-F0A45166E838 Q35690783-089DC8DB-FCC5-4964-B5B9-39C70ADE7826 Q35816355-3B25660E-294C-4A7F-933F-1A078C92757E Q36075087-705AFC75-798D-4150-AA49-7ED21B781E62 Q36567950-23C99FC0-45D8-4FFE-96E8-AAFDF24A96DB Q36723148-6F607228-9772-4A36-804A-4B7E7720B14E Q36799703-B8CC5BB3-900C-4870-8324-A255926B8959 Q37291238-40B5DE0A-93C0-43B9-B3C4-4F215B818629 Q37665974-BE5D9FA2-AF8B-4AF7-BC25-B408E743BC8F Q38072280-6F5E7C77-40E0-4337-BF50-79A6D7672061 Q38220772-45EECB4B-32B5-421B-8907-47DB1876A9E3 Q38365276-2F942C32-609F-49AE-89A4-70E41CC59FB1 Q38480164-F8B6A7D9-CD7B-443C-888C-F908B0C3DD32 Q38752448-666F3171-D575-4CB9-8DB4-2E9644C4479B Q38799232-34FB58ED-16C5-4043-8CC3-CCE43727BD20 Q38802973-33ED3203-A1D4-4C90-A530-DC766D04317A

P2860

Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q36402141

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Hedgehog pathway activation pa ...... alcoholic fatty liver disease.

@ast

Hedgehog pathway activation pa ...... alcoholic fatty liver disease.

@en

type

label

Hedgehog pathway activation pa ...... alcoholic fatty liver disease.

@ast

Hedgehog pathway activation pa ...... alcoholic fatty liver disease.

@en

prefLabel

Hedgehog pathway activation pa ...... alcoholic fatty liver disease.

@ast

Hedgehog pathway activation pa ...... alcoholic fatty liver disease.

@en

P1433

Q36402141-4095D604-7404-47C4-8839-BAC0FAE58EB6

P1476

Q36402141-7368642B-58F8-49A7-BC38-929BCC187B29

P2093

Q36402141-13A8931F-2C1A-4F52-AF8B-B16AFD3F7279

Q36402141-50DAFE9A-CCFB-4281-AD30-8B9BDA5B39B5

Q36402141-54DE1A90-DFD1-4159-99CD-19F160C4F13B

Q36402141-633D10D4-B9E6-4159-81D8-E277037BC87D

Q36402141-7531E21C-37D6-4E0B-9EA0-41084322C745

Q36402141-8EDD435C-D845-49F5-AF99-867B79E36595

Q36402141-CCB8F43B-3172-4E2C-B09C-8CE7BFE8369B

Q36402141-F66C0AA0-3CCA-41EB-B5AA-95DC8500974D

P2860

Q36402141-02D6AAEE-3F86-4B22-9DDC-4053F3F83012

Q36402141-0D66FD7A-A12F-4C9B-9541-1833A791D163

Q36402141-1EAB8CC6-9961-45AC-A5AD-A8C14C1F7805

Q36402141-2470AD63-0BC5-4053-B525-9EBC475EB1D2

Q36402141-28617393-13EB-46CC-9D71-B7C34A1DA9FB

Q36402141-3363595A-3941-4A5B-BDAE-8529C8F236A1

Q36402141-376B8CEF-3B32-498B-9656-56DE99A44414

Q36402141-68553196-2C55-4A8F-BB16-E2E64255AAD3

Q36402141-7A8595BE-D434-4EE7-8DC9-475AD45C0DF8

Q36402141-7D36E566-5E2A-44EC-9BBB-DE173D4E1830

P304

Q36402141-1AE7FB64-FDD4-4103-B4A5-19655A219144

P31

Q36402141-CD89DE42-628D-4DC9-B081-3ABA6138F5AD

P356

Q36402141-3E17D7DB-89D4-4CB9-81F7-103789880A37

P407

Q36402141-35B933F1-F355-443C-B9FD-EC2B736A3BB3

P433

Q36402141-3A87B407-26DD-4938-87CE-A15BE734DFC8

P478

Q36402141-53E74D47-A218-44E2-9F90-888F4086E0E8

P577

Q36402141-CE25969B-3CC6-4037-A72B-A9E6E0DDAF48

P5875

Q36402141-4A27EA37-C8E7-4506-B707-4DDBC58A85E1

P698

Q36402141-2DADA678-CE1A-416D-B506-A7CFC8CBB825

P932

Q36402141-29738BF3-6523-4D06-B05C-9A7C5C0EF6F7

P356

P1433

P1476

Hedgehog pathway activation pa ...... alcoholic fatty liver disease.

@en

P2093

Anna Mae Diehl

http://www.w3.org/2001/XMLSchema#string

Ayako Suzuki

http://www.w3.org/2001/XMLSchema#string

Aynur Unalp

http://www.w3.org/2001/XMLSchema#string

Cynthia D Guy

http://www.w3.org/2001/XMLSchema#string

James Burchette

http://www.w3.org/2001/XMLSchema#string

Manal F Abdelmalek

http://www.w3.org/2001/XMLSchema#string

Marzena Zdanowicz

http://www.w3.org/2001/XMLSchema#string

NASH CRN

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced thymocyte development in sonic hedgehog knockout embryos

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults

Hedgehog induction of murine vasculogenesis is mediated by Foxf1 and Bmp4

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis

Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice.

Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease.

Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate.

Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway.

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

P304

1711-1721

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.25559

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51976105

http://www.w3.org/2001/XMLSchema#string

P698

22213086

http://www.w3.org/2001/XMLSchema#string

P932

3499103

http://www.w3.org/2001/XMLSchema#string